RESULTS OF THERAPEUTIC DRUG MONITORING COMBINATION THERAPY OF ANTICONVULSANTS IN CLINICAL PRACTICS
Abstract
Abstract: this paper presents the results of therapeutic drug monitoring (TDM) of anticonvulsants – valproats and carbamazepins. Analysis include 800 patients with epilepsy in clinical practices, who received monotherapy and drug combinations. We determine plasma concentrations in two points: Cmin – before use next dose and Cmax – after next dose; concentration range for valproats – 50-150 mg/l, for carbamazepin – 4-12 mg/l. Plasma concentrations of valproats was statistically low in combination with carbamazepins than in monotherapy: Cmin 44,1±1,4 versus 62.1±2.0 (р<0,001) и Cmax 57.6±1.9 versus 76.5±2.4, without differences in daily doses. The frequency of achievement the therapeutic concentrations of valproats on valproat/carbamazepin combination was 34% versus 67% in monotherapy as result of inducing metabolism valproate acid by carbamazepin. For carbamazepin there was tendency for high frequency of achievement the therapeutic concentrations on combination treatment than on monotherapy – 86% versus 75.9%, but the doses of carbamazepin were also higher in combination therapy. However, plasma concentrations of carbamazepin were statistically higher only in combinations with other anticonvulsants exclude valproats: Cmin 8.0±0.2 versus 6.1±0.16 и Cmax 9.4±0.2 versus 7.3±0.18 (р<0,001) in monotherapy. The frequency of achievement the therapeutic concentrations for valproats and carbamazepin simultaneously in combination therapy was only 28.5%. This demonstrate the level of drug interactions in combination therapy of epilepcy especially with valproats and carbamazepin.
About the Authors
M. V. Leonova
Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
Yu. B. Belousov
Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
I. F. Tischenkova
Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
L. L. Shteinberg
Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
A. V. Sokolov
Pirogov Russian National Research Medical University, Moscow
Russian Federation
Russian Federation
References
1. Belousov Yu.B., Leonova M.V., Shteinberg L.L. i dr. Epilepsiya i paroksiz-malnye sostoyaniya. 2013; 5 (3): 6-16.
2. Gusev E.I., Belousov Yu.B., Gekht A.B., Bondareva I.B., Sokolov A.V., Tishchenkova I.F. The treatment of epilepsy: a rational dosing of anticonvulsants. [Lechenie epilepsii: ratsionalnoe dozirovanie antikonvulsantov]. SPb. 2000; 203 s.
3. Aldaz A., Ferriols R., Aumente D. et al. Pharmacokinetic monitoring of antiepileptic drugs. Farm Hosp. 2011; 35:326-39.
4. Ghodke-Puranik Y., Thorn C.F., Lamba J.K. et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenetics and genomics. 2013; 23 (4): 236-41.
5. Johannessen S.I., Landmark C.J. Antiepileptic drug interactions - principles and clinical implications. Current Neuropharmacology. 2010; 8: 254-67.
6. Meng H., Ren J., Lv Y. et al. Association study of CYP3A5 genetic polymorphism with serum concentrations of carbamazepine in Chinese epilepsy patients. Neurology Asia. 2011; 16 (1): 39-45.
7. Neels H.M., Sierens A.C., Naelaerts K. et al. Therapeutic drug monitoring of old and newer antiepileptic drugs. Clin Chem Lab Med. 2004; 42 (11): 1228-55.
8. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol. 2006; 61: 246-55.
9. Saruwatari J., Ishitsu T., Nakagawa K. Update on the genetic polymorphisms of drug-metabolizing enzymes in antiepileptic drug therapy. Pharmaceuticals 2010; 3: 2709-32.
10. Warner A., Privitera M., David B. Standards of laboratory practice: antiepileptic drug monitoring. Clinical Chemistry. 1998; 44 (5): 1085-95.
Review
For citations:
Leonova M.V., Belousov Yu.B., Tischenkova I.F., Shteinberg L.L., Sokolov A.V. RESULTS OF THERAPEUTIC DRUG MONITORING COMBINATION THERAPY OF ANTICONVULSANTS IN CLINICAL PRACTICS. Epilepsy and paroxysmal conditions. 2014;6(4):6-14. (In Russ.)
Views: 425
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
